Figure 2 displays the evidence network for the ACR50 mixed treatment comparisons meta-analysis. The diagram graphically displays the number of studies that comprise the evidence base for the analysis, and indicates the number of head-to-head and placebo-controlled studies underpinning the pairwise comparisons. Centered around placebo, there are eight biologic DMARDS displayed in boxes with a line connecting each drug-drug and each drug-placebo comparison. Next to each line is a number that represents the number of studies for each comparison. The diagram generally resembles a wagon wheel. There are two trials listed on the line connecting golimumab with placebo, seven trials between adalimumab and placebo, four trials between tocilizumab and placebo, two trials between rituximab and placebo, four trials between etanercept and placebo, three trials between anakinra and placebo, three trials between abatacept and placebo, and six trials between infliximab and placebo. Additionally, between abatacept and infliximab, there is a one trial listed that includes a head-to-head comparison between these two biologic DMARDs. There is a note at the bottom of the figure indicating that the total number of trials does not appear to equal 30, the total number of studies included in the analysis, because some trials have multiple arms that were included.

Figure 2Evidence network for ACR 50 mixed treatment comparisons

Note: The total number of trials does not appear to equal 30 (the total number of studies included in the analysis) because some trials have multiple arms that were included.

From: Results

Cover of Drug Therapy for Rheumatoid Arthritis in Adults: An Update
Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].
Comparative Effectiveness Reviews, No. 55.
Donahue KE, Jonas DE, Hansen RA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.